Publications 2005

d’Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 28 févr 2005;165(4):416‑23. Disponible sur:

Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther. 2005;10(4):563‑73. Disponible sur:

Girardi E, Sabin CA, d’Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 15 déc 2005;41(12):1772‑82. Disponible sur:

Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 1 juill 2005;39(3):284‑92. Disponible sur:

May M, Porter K, Sterne JAC, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol. oct 2005;58(10):1033‑41. Disponible sur:

Sabin C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS. 18 nov 2005;19(17):1995‑2000. Disponible sur: